TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05054660

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: caring chatbot
Description: The investigators will use the developed caring chatbot to provide care to the cases and to collect case treatment data and interaction data between the case and the caring chatbot.
Study: NCT05391191

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MitrAssist TRISKELE® transcatheter aortic valve system
Description: Patients were treated with MitrAssist TRISKELE® transcatheter aortic valve system
Study: NCT06104839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NXC736
Description: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration
Study: NCT06654557

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo beverage, kiwi-strawberry flavor (Part 1 and Part 2)
Description: 9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0% carbohydrate electrolyte solution with glycerol beverage (Part 1 only)
Description: 9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0% carbohydrate electrolyte solution without glycerol beverage (Part 1 only)
Description: 9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1% carbohydrate electrolyte solution with glycerol beverage (Part 1 only)
Description: 9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6% carbohydrate electrolyte solution with glycerol beverage (Part 1 only)
Description: 9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6% carbohydrate electrolyte solution without glycerol beverage (Part 2 only)
Description: 9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6% carbohydrate electrolyte solution with glycerol beverage (Part 2 only)
Description: 9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
Study: NCT05766748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azeliragon
Description: Azeliragon is an orally administered inhibitor of Receptor for Advanced Glycation Endproducts (RAGE) which is formulated as a 5mg hard gelatin capsule.
Study: NCT06654648

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined exercise nutrition intervention group
Description: Combination Product: Combined exercise and nutrition intervention Combined exercise and nutrition intervention for 12 weeks (an introductory phase 3 weeks, an expanded phase 3 weeks, and a maintenance phase 6 weeks). Exercise intervention (each 60-min session) includes stretching, resistance exercise, and aerobic exercise according to protocol. Nutritional intervention includes investigating dietary habits and calculate insufficient protein intake using Mini Nutritional Aseessment (MNA) and Korean Protein Assessment Tool (KPAT) to provide customized diet and high protein drink.
Study: NCT04736589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inetetamab
Description: Initial dose of 8mg/kg, completed in 90 minutes IV infusion, and then 6 mg/kg over 30-90 minutes IV infusion every 3 weeks.
Study: NCT06654648

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional medial care group
Description: Conventional medial care Conventional medical care service for 12weeks during intervention period. Usual care includes medical check-up and exercise and dietary counseling. They were given a brochure about exercise and protein rich foods at their first visit.~The control group patients maintain their usual amount of activity and diet during the 6-month evaluation period. usual activity and dietary habits.
Study: NCT04687722

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Aerobic Training.
Description: Participants will perform 2-5 minutes of low to moderate intensity warm up exercises and then 20 minutes of high intensity aerobic training at 80-90% of heart rate maximum increased gradually on treadmill and elliptical trainer and then 2-5 minutes of low to moderate intensity cool down exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity Aerobic Training
Description: Participants will perform 2-5 minutes of low to moderate intensity warm up exercises and then 20 minutes of low intensity aerobic training at 40-60% of heart rate maximum increased gradually on elliptical trainer and jogging and then 2-5 minutes of low to moderate intensity cool down exercises.
Study: NCT06398587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onvansertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onvansertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV
Study: NCT04736589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Oral 2mg, once a day.
Study: NCT06657014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mind-mindedness
Description: The Mind-Mindedness Training Intervention is a structured program designed specifically for primary caregivers of preschool-aged children (ages 4 to 7) who exhibit signs of social anxiety. This intervention is unique because it focuses on enhancing caregivers' understanding and responsiveness to their children's emotional and mental states through the concept of mind-mindedness.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mind-mindedness
Description: The Mind-Mindedness Training Intervention is a structured program designed specifically for primary caregivers of preschool-aged children (ages 4 to 7) who exhibit signs of social anxiety. This intervention is unique because it focuses on enhancing caregivers' understanding and responsiveness to their children's emotional and mental states through the concept of mind-mindedness.
Study: NCT06657495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD0015
Description: TD0015 is black, dark brown inside pilulae and has special smell of herbal, slightly sour then bitter taste.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD0015
Description: TD0015 is black, dark brown inside pilulae and has special smell of herbal, slightly sour then bitter taste.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TD0015 Placebo
Description: Placebo was packed in pack 5g
Study: NCT06656832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart Failure network care
Description: Patients will receive three visits within the first three months after randomization for improving heart failure therapy at a cardiologist or the outpatient heart failure clinic
Study: NCT06656013

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview
Description: After the preparation session, 4 sessions of motivational interviewing will be applied. Motivational interviewing techniques will be used in the interviews to target behavioral change.
Study: NCT06590116

Intervention type: OTHER
Group type: OTHER
Intervention: Physical therapy
Description: Patients with low back pain will receive a combination of education, spinal manipulative therapy, and exercise as prescribed by their physical therapist

Intervention type: OTHER
Group type: OTHER
Intervention: Physical therapist provider
Description: Physical therapists will provide a combination of education, spinal manipulative therapy, and exercise to their patients with low back pain participating in the study
Study: NCT06603883

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) by nasal jejunal tube
Description: FMT was administered via a naso-jejunal tube to inject 50ml commercial intestinal bacterial suspension into the jejunum.
Study: NCT06479603

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nintedanib
Description: The subjects will receive oral nintedanib. It will be prescribed to be taken after meals with 12 hrs gap between doses. The drug will be started at a dose of 100 mg twice daily. After 2 weeks, the dose will be titrated up to 150 mg twice daily, which will be continued till the end of 52 weeks. The standard-of-care immunosuppressive treatment will be continued along with the study drug (nintedanib). In case of intolerance to the 300 mg/day dose of nintedanib, the dose will be reduced to 100 mg twice daily. In case of severe adverse effects, the drug will be stopped and reintroduced after a period of up to 1-4 weeks. A dose of 100 mg twice daily will be started and continued. One attempt to titrate the dose up to 150 mg twice daily will be permitted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: The subjects will receive the standard-of-care immunosuppressive treatment alone that may include glucocorticoids and other steroid-sparing agents that the subject would already be receiving.
Study: NCT05791058

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided pericapsular nerve group shoulder block
Description: The patient's arm is placed in external rotation and abducted at 45 degrees. A linear ultrasound probe will be placed longitudinally between the coracoid and the humeral head. After defining the humeral head, the tendon of the subscapular muscle and the deltoid muscle over it, a 50-mm needle will be inserted using the ''in plane'' technique. When the needle pass through the deltoid muscle and touched the subscapularis tendon, a bone-like hard tissue will be felt and the needle could not be advanced further. The needle tip will be placed between the deltoid muscle and subscapularis tendon, and 20 cc of 0.25% bupivacaine hydrochloride with 4mg dexamesathone will be injected

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided suprascapular and axillary nerve block
Description: The patient will be positioned in a semi-recumbent position with the operating arm on the contralateral shoulder. The probe will be kept over the scapular spine to identify the trapezius and the supraspinatus muscle. Then, it will be moved laterally to identify the concavity of the supraspinatus fossa and the hyper-echoic fascia of the supraspinatus muscle. In the concavity of the fossa, the suprascapular artery and the suprascapular nerve run in close proximity. 10 ml of 0.25% bupivacaine with 2mg dexamethasone will be injected below the supraspinatous fascia then the posterior surface of the humerus will be visualised in the short axis view. So, the AN and posterior circumflex artery will be visualised longitudinally. 10 ml of 0.25% bupivacaine with 2mg dexamethasone will be injected into space

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia without nerve block
Description: this group will receive general anesthesia without nerve block
Study: NCT05591911

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine PCR testing
Description: The urine PCR panel will be performed to evaluate the bacterial growth in the patient's urine who is admitted with acute urinary tract symptoms.
Study: NCT04695977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMP-001
Description: Subjects will receive CMP-001 10 mg IT weekly for 7 doses after which CMP-001 will be administered every 3 weeks (Q3W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 360 mg IV is administered Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 360 mg IV is administered Q3W.
Study: NCT05860101

Intervention type: OTHER
Group type: OTHER
Intervention: Compassion-Focused Therapy
Description: Compassion Focused Therapy (CFT) is based on the premise that we have three emotion regulation systems, the threat, drive and soothing systems. It has been suggested that our psychological wellbeing is dependent on maintaining a balance between these three systems, and if we lose this balance, e.g. the threat or drive systems become more dominant, then we start to experience emotional difficulties (Gilbert, 2009). In this study, participants are given various exercises to develop their soothing system, and help them to balance overactive threat.

Intervention type: OTHER
Group type: OTHER
Intervention: Compassion-Focused Therapy
Description: Compassion Focused Therapy (CFT) is based on the premise that we have three emotion regulation systems, the threat, drive and soothing systems. It has been suggested that our psychological wellbeing is dependent on maintaining a balance between these three systems, and if we lose this balance, e.g. the threat or drive systems become more dominant, then we start to experience emotional difficulties (Gilbert, 2009). In this study, participants are given various exercises to develop their soothing system, and help them to balance overactive threat.
Study: NCT06091072

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Image-guided navigation
Description: A patient-specific 3D model will be created using an available pre-operative SPECT/CT scan. Pre-operatively, three electromagnetic patient trackers will be attached to the patients' skin, close to the pelvis, allowing tracking the patient's position during surgery. After anesthesia and before the skin disinfection procedure, the patient is placed in the final surgical position, where an intra-operative CBCT scan is performed required for the image-guided surgery workflow. During surgery, the preoperative images and 3D model will be visible for the surgeon together with a blunt-tip electromagnetic pointer enabling surgical navigation during robotic surgery. Anatomical structures will be used to validate the accuracy of the navigation. When the target is identified by the surgeon, the pointer is used to store the location digitally. Scheduled standard clinical 99mTc will be used as validation for target(s) identification.
Study: NCT04839575

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latiglutenase
Description: Administered orally (daily)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally (daily)
Study: NCT06398587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrocardiography
Description: Undergo electrocardiography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrocardiography
Description: Undergo electrocardiography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT05040880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmione plus 80/12.5mg
Description: Test drug (Fixed-dose combination drug of telmisartan 80mg and hydrochlorothiazide 12.5mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmione plus 80/12.5mg
Description: Test drug (Fixed-dose combination drug of telmisartan 80mg and hydrochlorothiazide 12.5mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micardis plus 80/12.5mg
Description: Reference drug (Fixed-dose combination drug of telmisartan 80mg and hydrochlorothiazide 12.5mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micardis plus 80/12.5mg
Description: Reference drug (Fixed-dose combination drug of telmisartan 80mg and hydrochlorothiazide 12.5mg)
Study: NCT06100432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS5055 200mg
Description: 1x1 caplet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS5055 200mg
Description: 1x1 caplet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo DLBS5055
Description: 1x1 caplet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin (Vitamin C 500mg + Vitamin E 100IU + Beta Carotene 10000IU)
Description: 1x2 caplets
Study: NCT06398587

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET
Study: NCT06100432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multivitamin (Vitamin C 500mg + Vitamin E 100IU + Beta Carotene 10000IU)
Description: 1x2 caplets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Multivitamin
Description: 1x2 caplets
Study: NCT05992467

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Enhancement for Caregivers (WECARE)
Description: WECARE behavioral intervention is guided by behavioral theories aimed to increase participants' caregiving mastery, enhance self-care, and improve psychosocial wellbeing. Participants will receive multimedia content on their WeChat account on cellphone or tablet, including short video clips, pictorial messages, short articles, and audio recordings 6 days a week, for 7 weeks.
Study: NCT06203002

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (blinded)
Description: LX9211 matching placebo tablets
Study: NCT05428943

Intervention type: DRUG
Group type: OTHER
Intervention: OPT101
Description: 15-mer peptide derived from the sequence of mouse CD154.

Intervention type: DRUG
Group type: OTHER
Intervention: OPT101
Description: 15-mer peptide derived from the sequence of mouse CD154.
Study: NCT06368869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Livento press veneers luted with dual cured resin cement
Description: Veneers will be fabricated using Lithium disilicate (Livento® Press) ceramic and luted using Bifix QM dual cured cement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Livento press veneers luted with light cured resin cement
Description: Veneers will be fabricated using Lithium disilicate (Livento® Press) ceramic and luted using Bisco choice 2 light cured cement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Celtra duo veneers luted with dual cured resin cement
Description: Veneers will be fabricated using Zirconia-reinforced lithium silicate (Celtra® Press) ceramic and luted using Bifix QM dual cured cement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Celtra duo veneers luted with light cured resin cement
Description: Veneers will be fabricated using Zirconia-reinforced lithium silicate (Celtra® Press) ceramic and luted Bisco choice 2 light cured cement
Study: NCT05807321

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fecobionics
Description: Fecobionics is a novel device to be inserted through the anal canal into rectum for studying defecation. Anorectal manometry and balloon expulsion test may be used as reference. Anorectal manometry and balloon expulsive test are standard methods for anorectal functional measurement.
Study: NCT05914857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg Tab
Description: Dapagliflozin Tablets, Oral, 10mg, Once daily

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: lifestyle interventions
Description: Consisting of 30 minutes of moderate-intensity exercise every day and a reduction of 300 calories in the total diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle interventions
Description: Consisting of 30 minutes of moderate-intensity exercise every day and a reduction of 300 calories in the total diet
Study: NCT04721795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin with standard anti tuberculosis drugs
Description: Participants will receive oral 30/40mg of atorvastatin daily for 2 months together with oral doses of standard antituberculosis drugs consisting of Rifampicin, INH, Ethambuthol and pyrazinamide for 2months. At the end of 2months, participants will continue with only standard anti tuberculosis drugs, Rifampicin and INH for 4months.Doseage of antituberculosis drugs are dependent on weight

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard anti tuberculosis drugs only
Description: Participants will receive oral doses of standard antituberculosis drugs consisting of Rifampicin, INH, Ethambuthol and pyrazinamide for 2months. At the end of 2months, participants will continue with only standard anti tuberculosis drugs, Rifampicin and INH for 4months.Doseage of antituberculosis drugs are dependent on weight
Study: NCT06281340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: Each session will last approximately 50-60 minutes. Each session is composed of 10 techniques, 9 of which correspond to manual interventions commonly used in the field of manual therapy and adapted to patients with hemophilic arthropathy, according to the criteria previously established in studies that assess the safety of manual interventions in hemophilic arthropathy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo manual therapy
Description: Each session will last approximately 50-60 minutes. Each session consists of the placebo application of 10 techniques, 9 of which correspond to manual interventions commonly used in the field of manual therapy and adapted to patients with hemophilic arthropathy, according to criteria previously established in studies that assess the safety of manual interventions in hemophilic arthropathy. In the techniques there will be no joint sliding, manipulations or myofascial inductions, being the only stimulus the contact of the physiotherapist with his hands and the pressure exerted with these, on the ankle.
Study: NCT06398587

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT06236893

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VH-01 vaginal suppository tablet
Description: Participants will be instructed to take VH-01 Days 1, 4, 7, 14, and 21 of Month 1 and Days 1 and 14 of Months 2 and 3.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaginal suppository tablet
Description: Participants will be instructed to take the placebo on Days 1, 4, 7, 14, and 21 of Month 1 and Days 1 and 14 of Months 2 and 3.